Company Overview of GlaxoSmithKline Pakistan Ltd.
GlaxoSmithKline Pakistan Limited manufactures and markets research based ethical specialties, other pharmaceutical, and consumer products in Pakistan and internationally. It operates through two segments, Pharmaceuticals and Consumer healthcare. The company deals in anti-infective, respiratory, vaccines, dermatological, analgesics, oncology, urology, central nervous system, allergy, cardiovascular, and vitamins therapy areas. It offers its pharmaceutical products primarily under the Augmentin, Seretide, Amoxil, Velosef, Zantac, and Calpol brands; consumer healthcare products under the Panadol, Horlicks, Sensodyne, and ENO brands; and vaccines under the Synflorix, Infanrix Hexa, Rotarix, Havr...
35, Dockyard Road
Key Executives for GlaxoSmithKline Pakistan Ltd.
GlaxoSmithKline Pakistan Ltd. does not have any Key Executives recorded.
GlaxoSmithKline Pakistan Ltd. Key Developments
GlaxoSmithKline Pakistan Announces Executive Changes
Nov 18 15
GlaxoSmithKline Pakistan Ltd. announced that Mr. M Salman Burney, Chief Executive Officer shall officially retire from the company on November 21, 2015 and will cease to hold the office of CEO. Consequently the board of directors have appointed Mr. Mohammed Azizul Huq as Chief Executive Officer effective November 22, 2015.
GlaxoSmithKline Pakistan Ltd., Special/Extraordinary Shareholders Meeting, Nov 30, 2015
Nov 6 15
GlaxoSmithKline Pakistan Ltd., Special/Extraordinary Shareholders Meeting, Nov 30, 2015. Agenda: To pass special resolution for demerger of business comprising all assets, rights, quotas& obligations of consumer healthcare business of GSK Pakistan with & into GlaxoSmithKline Consu.Healthcare.
GlaxoSmithKline Pakistan Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Oct 26 15
GlaxoSmithKline Pakistan Ltd. reported earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported sales of PKR 5,902.1 million compared to PKR 5,740.1 million, profit from operations of PKR 1,533.4 million compared to PKR 635.0 million, profit before taxation of PKR 1,489.2 million compared to PKR 629.1 million and profit after taxation of PKR 1,298.7 million or PKR 4.08 per share compared to PKR 400.0 million or PKR 1.26 per share for the last year.
For the nine months, the company reported sales of PKR 17,676.7 million compared to PKR 17,022.0 million, profit from operations of PKR 2,753.9 million compared to PKR 1,831.1 million, profit before taxation of PKR 2,699.9 million compared to PKR 1,831.1 million and profit after taxation of PKR 2,131.6 million or PKR 6.69 per share compared to PKR 1,192.7 million or PKR 3.75 per share for the last year.
Similar Private Companies By Industry
Recent Private Companies Transactions